News for Castle Biosciences Inc Stock (CSTL)

Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies

Business Wire • 05/03/23

Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event

Business Wire • 04/28/23

DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients

Business Wire • 04/25/23

TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett's Esophagus Patients with Low-Grade Dysplasia

Business Wire • 04/20/23

Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3

Business Wire • 04/19/23

Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference

Business Wire • 04/12/23

7 Value Stocks to Buy for Long-Term Growth

InvestorPlace • 03/26/23

Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study

Business Wire • 03/18/23

Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting

Business Wire • 03/10/23

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

Business Wire • 03/08/23

Castle Biosciences, Inc. (CSTL) Q4 2022 Earnings Call Transcript

Seeking Alpha • 03/03/23

Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results

Business Wire • 02/28/23

Castle Biosciences' Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing

Business Wire • 02/24/23

Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors

Business Wire • 02/22/23

Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines

Business Wire • 02/09/23

Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

Business Wire • 02/07/23

Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year

Business Wire • 02/01/23

Castle Biosciences' Medical Director to Present at the Precision Medicine World Conference 2023

Business Wire • 01/23/23

Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences' Skin Cancer Test Portfolio

Business Wire • 01/17/23

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results

Business Wire • 01/09/23

Castle Biosciences: Potential To Re-Rate With Supportive Fundamentals, Technicals, Underlying Market

Seeking Alpha • 12/15/22

Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

Business Wire • 11/21/22

Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

Business Wire • 11/17/22

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

Business Wire • 11/15/22

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

Business Wire • 11/14/22